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ABSTRACT
Objectives: This study describes the early experience of
robotic prostatectomy exclusively at a teaching commu-
nity hospital.
Methods: This is a retrospective report of 153 consecutive
patients on whom 4 physicians were the operating sur-
geon.
Results: The average hospital stay was 1.5 days, the mean
operative time was 175 minutes, and the estimated oper-
ative blood loss was 300mL. The perioperative compli-
cation rate was 7.8% (12/153). The prostate-specific anti-
gen failure rate was 2% (2/114). Urinary continence was
maintained in 98% of patients 9 months after surgery.
Postoperative Gleason scores differed significantly from
preoperative biopsy results (P0.001). Pathological re-
cords reported positive margins in 35% (54/153) of spec-
imens. T3 tumors had positive margins more than twice as
often as T2 tumors (P0.002). Surgeon experience corre-
lated with shorter operative times (P0.001), but not with
positive margins. Increasing body mass index was associ-
ated with increased operating time (P0.001).
Conclusions: Robotic prostatectomy appears to be a safe
and successful option for prostate cancer treatment in a
teaching community hospital.
Key Words: Prostatic neoplasms, Robotics, Prostatec-
tomy, Hospitals, Community.
INTRODUCTION
The 5-year survival rate for local and regional stages of
prostate cancer is close to 100%, the 10-year rate is 91%,
and the 15-year rate is 76%.1 Treatment options for early-
stage disease are dependent on patient age and physical
condition. Brachytherapy, external beam radiation, sur-
gery, and observation are all options for managing early
stages.1 Although expectant management of early-stage
prostate cancer is an option, caution should be used since
treatment provides a higher cure rate than observation.
The National Comprehensive Cancer Network (NCCN)
recommends no further workup or treatment for asymp-
tomatic prostate cancer patients with comorbidities that
portend life expectancy of 5 years unless the patient has
high-risk cancer, defined as either a bulky stage T3 or T4
tumor or a tumor with a Gleason score 8.2
Open, laparoscopic, and robotic surgery effect a high cure
rate in early-stage disease. Open and robotic surgery re-
port similar rates of positive margins3 and prostate-spe-
cific antigen (PSA) recurrence.4 Furthermore, in a study
comparing laparoscopic and robotic prostatectomies,
postoperative PSA levels at 12 months were undetectable
in 97.5% and 95% of cases, respectively.5
More than half the radical prostatectomies performed in
the United States are robot assisted.6 The advantages of
using a robot include reduced surgeon fatigue, greater
magnification, and 6 or more degrees of articulating free-
dom.6 Elimination of hand tremor improves the precision
of dissection.7 Robotic prostatectomies are associated with
decreased blood loss, fewer transfusions, and a faster
recovery rate compared to open procedures.7,8 Robotic
operations, however, have a steep learning curve.
Most reports on robotic prostatectomies come from aca-
demic university programs. The purpose of this study was
to assess the preliminary safety and effectiveness of this
procedure exclusively at a teaching community hospital.
MATERIALS AND METHODS
Study Design
This is a retrospective analysis of patients electing robotic
radical prostatectomy between January 1, 2007 and Sep-
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SCIENTIFIC PAPERtember 30, 2007 at a single teaching community institu-
tion. Exemption from our institution’s institutional review
board was obtained for this project. All operations were
performed on the da Vinci robot (Intuitive Surgical, Inc.,
Sunnyvale, CA, USA), which was purchased 1 year before
this study. Four surgeons performed 153 radical prostate-
ctomies during the study period.
PSA
PSA results were obtained from patient charts in surgeons’
offices. The preoperative value was the test performed
closest to the date of surgery; the postoperative values
were tests collected closest to 9 months after surgery (2
months). We chose 9 months because of surveillance
practice among our surgeons. PSA failure is defined as
0.5ng/mL.9,10
Gleason Score
Preoperative Gleason scores were determined from pa-
thology reports in surgeons’ offices; these may have come
from multiple institutions. The postoperative Gleason
score was obtained from the prostatectomy pathology
report from our institution. For purposes of assigning risk
categories, we used NCCN definitions: low-riskGleason
score 2 to 6, intermediate-risk7, high-risk8t o1 0 .
Operative Data, Demographics, and
Tumor Characteristics
Operative data and patient demographics were collected
from the hospital database. Estimated blood loss was ob-
tained from the operative records. Nine cases that recorded
blood loss as “minimal” were assigned the value of 50cc, the
lowest recorded value of blood loss for all surgeries. Com-
plications during surgery and within 30 postoperative days
were identified through International Classification of Dis-
eases, 9th Edition (ICD-9) codes. Tumor stage, tumor mar-
gins, prostate weight, and tumor volume were taken from
pathology reports. A positive margin was defined as the
presence of any cancer cells at the surgical margin, whether
unifocal or multifocal. The sites of positive margins were
recorded. Close margins were defined as tumor cells within
0.1mm of the surgical margin.
Urinary Continence
Urinary continence at 9 months was determined from
physician progress notes. Continence was defined by the
need for perineal pads: patients using 1 pad per day
were classified as continent; those using 2 or more, incon-
tinent.5,7
Statistics
Comparisons for numeric variables were done using the t
test, while Fisher’s exact test was used for categorical
variables. Linear regression examined the relationship be-
tween various factors and operating time. A normal prob-
ability plot was used to check whether the residuals con-
formed to a normal distribution, and differences in beta
values (DFBETAs) were examined to evaluate whether a
particular observation had a disproportionate influence
on parameter estimates. Logistic regression was used to
assess relationships among surgeons, surgical margins,
and pathological factors. The Hosmer-Lemeshow good-
ness of fit test assessed whether the model reasonably
reflected the observed data. Data were analyzed using SAS
version 9.1 (SAS Institute, Inc., Cary, NC).
RESULTS
Table 1 lists the clinicopathological characteristics of
the study patients.
Weight Distribution
Twenty-six percent (40/153) of patients had a normal
body mass index (BMI25), 47% (72/153) were over-
weight (BMI25 to 30), and 27% (41/153) were obese
(BMI30). Six patients (4%) had a BMI35.
PSA
The average preoperative PSA was 6.00ng/mL (range, 0.87
to 20.6). Nine months after surgery, all patients with fol-
low-up data (114) had normal PSAs, and 92% (105/114)
had undetectable levels (0.1ng/mL). Of the 9 patients
with detectable PSAs, 5 had positive surgical margins,
while 4 had negative margins. Only 2 (2%) patients of the
114 had PSA failure (0.5ng/mL); one had a PSA of
0.5ng/mL, the other 1.61ng/mL. Both patients had nega-
tive surgical margins. One patient was lost to follow-up,
and the second is undergoing evaluation for recurrence.
We did not have data for 39 of the original 153 patients
due to patient follow-up with physicians other than the
operating surgeons.
Gleason Score
When comparing pre- and postoperative Gleason scores,
40% (61/153) of patients’ scores changed (P0.001), result-
ing in a shift of risk category in all instances (Figure 1). Five
percent (8/153) of patients moved from a low- or inter-
mediate-risk preoperative Gleason score to a high-risk
Robotic Radical Prostatectomy at a Teaching Community Hospital: Outcomes and Safety, Padavano J et al.
JSLS (2011)15:193–199 194category. Two percent (3/153) of patients had a high-risk
preoperative score but an intermediate-risk postoperative
score. The pre- and postoperative Gleason scores of both
patients with PSA failures were 6.
Operative Time
The average operating time was 175 minutes (range, 105
to 331). Factors examined for an effect on operating time
were patient age, BMI, and surgeon. Linear regression
showed that patient BMI (P0.0010) and surgeon
(P0.0001 for surgeons B, C, and D compared to A) were
significantly associated with operating time. Operating
times were longer by an estimated 38 minutes to 112
minutes for surgeons B, C, and D compared to A, the latter
having the highest experience by volume (Figure 2).
Controlling for surgeon, operating times increased by ap-
proximately 9.5 minutes for each 5-point increase in BMI
(Figure 3). Patient age was not significantly associated
with operating time (P0.2829).
Tumor Stage
Eighty-six percent (132/153) of prostate carcinomas were
T2 tumors; 14% (21/153) were T3. Three patients had
lymph node dissection; all these were negative for metas-
tasis. In 3 patients (2%) the seminal vesicles were positive
for tumor infiltration.
Figure 1. Gleason score risk categories before and after surgery.
Figure 2. Operating time by surgeon experience.
Table 1.
Clinicopathological Results. PSA Data Available for 114
Patients and Urinary Continence Data for 126 Patients
Characteristic Mean (Range) or
n (%)
Age (years) 61 (44–81)
BMI
a 27.7 (19.2–41.6)
Preoperative PSA
a (ng/mL) 6.0 (0.87–20.6)
2 4 (2)
2–4.9 67 (44)
5–7.9 54 (36)
8–9.9 14 (9)
10 13 (9)
Surgical Time (minutes) 175 (105–331)
Estimated Blood Loss (mL) 276 (50–1300)
Aborted Procedures 0
Prostate Weight (g) 46 (23–99)
Prostate Volume (cm
3) 75.2 (26.4–196.6)
Tumor Percentage of Removed Prostate 13% (1–90)
Tumor Volume (cm
3) 8.9 (0.37–109.4)
Postoperative Pathological Stage
T2 3 (2.0)
T2a 16 (10.5)
T2c 113 (73.9)
T3 2 (1.3)
T3a 16 (10.5)
T3b 3 (2.0)
Preoperative Gleason Score 6.4 (6–9)
Postoperative Gleason Score 6.7 (6–9)
Positive Surgical Margins 54 (35)
T2 40 (30)
b
T3 14 (67)
c
Patients With Resected Lymph Nodes 3 (2.0)
Positive Lymph Nodes 0
Positive Seminal Vesicles 3 (2.0)
Complications 12 (7.8%)
d
Hospital Stay 1.5 (1–10) days
Pad Use at 9 months
0 Pads 89 (71)
1 Pad 34 (27)
2 Pads 3 (2)
Number of PSA Failures 2 (1)
a BMIBody Mass Index, PSAProstate-Specific Antigen.
b proportion of T2 tumors with positive margins.
c proportion of T3 tumors with positive margins.
d see Table 2 for details.
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Thirty-five percent (54/153) of specimens had positive
surgical margins; 4% (6/153) had close margins. Both
patients with PSA failure had negative margins. Of the 54
patients with positive tumor margins, 25 (46%) were uni-
focal. Margin status was significantly related to tumor
volume (P0.05) (Figure 4). In a logistic regression,
factors independently associated with positive margins
were: T3 stage (P0.0140, odds ratio [OR]4.0, 95% con-
fidence interval [CI]1.3 to 12.0), tumors occupying a
greater proportion of the prostate (P0.0382, OR1.2 for
each 5% increase, 95% CI1.01 to 1.5), and prostate vol-
umes 90cm
3 (P0.0186, OR3.0, 95% CI1.2 to 7.6).
Margin status was not related to surgeon experience. More
than 50% (37/73) of positive margins were in the apical
region of the prostate. This was the most common positive
margin for both T2 (55%, 29/52) and T3 tumors (37%,
8/21) (Table 2).
Complications
No robotic operations were converted to laparotomy.
Of 153 cases, 12 (7.8%; 95% CI:4.1 to 12.9) sustained
perioperative complications (Table 2). BMI did not
significantly affect complication rates (P0.17). Pa-
tients with complications had a median BMI of 26.0
(Inter-quartile range [IQR]24.2 to 33.6), while those
without complications had a median BMI of 27.2
(IQR24.7 to 30.2).
Urinary Continence
Data were available for 126 of the 153 patients (82%). At
9 months, 3 (2.4%, 95% CI:0.0 to 5.0%) of the 126 patients
were incontinent, defined as the use of more than one
perineal pad per day.
DISCUSSION
Robotic prostatectomy at our teaching community hospi-
tal proved to be an effective operation for prostate cancer
Figure 3. Operating time according to patient BMI (r
20.63).
Figure 4. Surgical margins by mean tumor volume (P0.05).
Table 2.
Location of Positive Margins and Perioperative Complications
Positive Margins: T2 N (%)
Apical 29 (55)
Anterior 9 (17)
Posterior 6 (12)
Posterolateral 2 (4)
Lateral 4 (8)
Bladder 2 (4)
Positive Margins: T3
Apical 8 (37)
Anterior 2 (10)
Posterior 5 (24)
Posterolateral 0 (0)
Lateral 5 (24)
Bladder 1 (5)
Perioperative Complications
Adynamic Ileus 1 (0.7)
Anastomosis Leak 3 (2.0)
Deep Venous Thrombosis 1 (0.7)
Nerve Palsy 1 (0.7)
Obstruction 1 (0.7)
Rectal Laceration 1 (0.7)
Urinary Retention 2 (1.3)
Urinary Tract Infection 2 (1.3)
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lected the candidates for robotic operations, the cohort
included obese patients and patients with large prostates.
Forty-seven percent (72/153) of patients were overweight,
and 27% (41/153) were obese. The average prostate vol-
ume of 75.2cm
3 is larger than the size reported in other
series.11,12 We found that BMI was significantly related to
operative time, as others have reported.13 Despite the high
BMIs and large prostate volumes, the operations were
performed successfully with no conversions to open sur-
gery. BMI did not appear to be related to complications, as
others found it to be.14
While morbidity was low and mortality was zero in this
study, there was a significant relationship between sur-
geon experience and operative time. Robotic prostatecto-
mies have been associated with a steep learning curve.
Surgeon technique and experience may also have an
impact on margin status, though our study did not find a
significant association. This may be due to the relatively
low number of cases for some of the surgeons, resulting in
insufficient power to detect a difference between sur-
geons.
Other indicators of robotic prostatectomy safety in this
series are the minimal blood loss and the short hospital-
ization (average 1.5 days). These data are also comparable
to data from other series at university medical cen-
ters.7,8,11,15
The success or effectiveness of radical prostatectomies is
commonly measured by postoperative PSA levels. At 9
months, all recorded PSA values (114) were within the
normal range. Ninety-two percent (105/114) had unde-
tectable levels (0.1ng/mL), while 2% (2/114) had PSA
failure (defined as 0.5ng/mL). The proportion of pa-
tients with an undetectable PSA is comparable to that of
other studies.5,16 We defined a level of 0.5ng/mL as PSA
failure based on past studies. Partin et al10 reported that
81% of patients with PSA levels 0.5ng/mL within 12
months following surgery had biopsy-proven local fail-
ures and that the majority of patients with bone scans
showing distant metastases had PSA levels reach
0.5ng/mL within 12 months. Furthermore, in a series of
more than 5,000 patients,9 no patients with values
0.5ng/mL had evidence of cancer. Our 9-month fol-
low-up may have failed to identify some patients who
may have had PSA failure by 12 months. However, we
believed that examining the earliest cases performed
would give a more critical assessment of the efficacy of
this procedure in a teaching community hospital setting.
This resulted in a shorter follow-up, because the surgeries
took place only 9 months before the start of the study.
The lymph node dissection rate is a reflection of the normal
practice patterns in our community, including cases of T3
tumors, and was not associated with the robotic operation
itself; it is similar to the rate for open operations.
The prevalence of positive surgical margins in our study
was 35% (54/153), which is within the range reported in
the literature, 10% to 45.4%.12,17,18 Prevalence of positive
surgical margins is traditionally considered a measure of
operative outcome, although their prognostic significance
is controversial. Those who believe that positive surgical
margins negatively impact patient outcomes report an
absolute decrease in progression-free survival of approx-
imately 20% (both 5- and 10-year rates).19 However, other
studies have found that recurrence occurs primarily with
nonorgan-confined tumors20 and that patients with low-
risk disease have a favorable long-term outcome regard-
less of margin status and may even be expectantly man-
aged.21 A recent multivariate analysis22 showed that while
a positive margin was associated with an increased risk of
biochemical recurrence, local recurrence, and salvage
treatment, it was not significantly related to systemic pro-
gression, cancer-specific death, or overall mortality.
Certain factors examined in this study are consistently
related to positive margins in the literature, including T3
stage15 and a higher proportion of the prostate replaced
by tumor.23 We found similar relationships between these
factors and positive margin status (T3 stage OR4.0,
OR1.2 for each 5% increase in proportion of the
prostate occupied by tumor). Fourteen percent (21/153)
of the cases in our series were T3 tumors. This propor-
tion is in the middle of the range reported in other
studies (0% to 24%).15,16
Our data also demonstrate that margin status was related
to prostate size 90mL. In another report, smaller prostate
size (ie, 40mL) was associated with a larger proportion
of prostate replaced by tumor, greater tumor density, and
a greater chance of extraprostatic tumor extension, but not
with positive surgical margins.23 However, several other
reports24–27 indicate a relationship between smaller pros-
tate size and positive margin status. We note that “smaller”
prostate size is a relative term and is defined differently
among the studies that have examined this parameter.23–27
Furthermore, a review of studies on this subject shows
that the same prostate size is associated with a highly
variable rate of positive margins.24–27 Additional explora-
tion of the potential relationship between prostate volume
and positive surgical margins is warranted.
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margins for both T2 and T3 cancers was the apex, which
others have reported.28 Specific features of positive surgi-
cal margins appear to affect disease recurrence, including
whether they are multifocal and/or extensive, their num-
ber, and locale.29 Of the 54 patients in this study who had
positive tumor margins, 25 (46%) were positive at only a
single margin. Since only 2 of our patients had PSA fail-
ures, both with negative margins, and very few had de-
tectable PSA levels, we could not assess an association
between margin status and PSA persistence.
Regardless of the conflicting reports on margin status, due
to the possible negative impact of positive surgical mar-
gins, surgeons must ensure that their own capability of
attaining clear margins is sustained with the adoption of
new surgical modalities. Institutions, likewise, should be
cautious that the rate of positive surgical margins does not
fall outside the normal range reported in the literature
after the deployment of robots.
The complication rate in this study was 7.8% (12/153),
which is similar to that of other studies.11,15 Complications
varied, but were also comparable to those of other stud-
ies.12,15 There were no conversions to open surgery, and
no mortalities.
The Gleason score is the strongest predictor of postoper-
ative recurrence.23 Of interest was the fact that 40% (61/
153) of cancers had different pre- and postoperative Glea-
son scores, causing these patients to shift to a different risk
category. However, only 10 patients had what we would
consider a significant shift, that is, in or out of the high-risk
class. Other centers have also found differences in pre-
and postoperative Gleason scores. The number and
length of core biopsies can impact grading error.30 Both
patients with PSA failures had pre- and postoperative
Gleason scores of 6. Again, the low PSA failure rate in our
study prevents an assessment of an association with Glea-
son scores.
Urinary continence is an important assessment of patients’
quality of life following radical prostatectomy. Our study’s
continence rate at 9 months, 97% (123/126), compares
very favorably to that of other studies.15 However, assess-
ment of continence 2 years after surgery might be more
valuable, because recovery of urinary control may require
up to 120 weeks.15
CONCLUSION
Our study indicates that robotic prostatectomy can be
safely and effectively instituted at a teaching community
hospital. Blood loss during surgery was low, no transfu-
sions were necessary, and most patients were in the hos-
pital less than 2 days. Approximately 8% of patients (12/
153) had postoperative complications. There were no
mortalities. Maintenance of urinary continence was high,
and PSA failure was low at 9 months.
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